Search
01/08/2024
The impact of diagnosis delay on European patients with generalised myasthenia gravis
Cortes-Vicente, E, Borsi, AJ, Gary, C, Noel, WGJ, Lee, JMS, Karmous, W, Zhang, QY, Gandhi, KH, Batista, AE, Decourcy, JJ, Barlow, SG, Birija, SL, Gibson, GA. The impact of diagnosis delay on European patients with generalised myasthenia gravis. Annals of Clinical and Translational Neurology. 2024; 11(9)DOI:10.1002/acn3.52122. PMID:39090840. IF:3.900(Q1/3D).
01/08/2024
ANTI-HNK-1 IGM AND SNFL LEVELS ARE POTENTIAL BIOMARKERS FOR MONITORING DISEASE ACTIVITY IN ANTI-MAG NEUROPATHY
Pascual-Goñi, E, Martín-Aguilar, L, Lleixà, C, Mariscal, A, Tejada-Illa, C, Caballero-Avila, M, Martinez-Hernandez, E, Serfim, A, Moga, E, Rojas-García, R, López-Pardo, J, Novelli, S, Gallardo, E, Sabater, L, Querol, L. ANTI-HNK-1 IGM AND SNFL LEVELS ARE POTENTIAL BIOMARKERS FOR MONITORING DISEASE ACTIVITY IN ANTI-MAG NEUROPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
ANTI-CASPR1 AUTOIMMUNE NODOPATHY AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION
Collet-Vidiella, R, Mederer-Fernandez, T, Caballero-Avila, M, Tejada-Illa, C, Pascual-Goñi, E, Martín-Aguilar, L, Lleixà, C, Querol, L. ANTI-CASPR1 AUTOIMMUNE NODOPATHY AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
ANTI-CASPR1 ANTIBODIES ARE ASSOCIATED WITH HLA-DRB1*03:01 ALLELES
Lleixà, C, Martínez-Martínez, L, Pascual-Goñi, E, Martín-Aguilar, L, Caballero-Avila, M, Collet, R, Illa, CT, Gallardo, E, Boera-Carnicero, G, Calahorro, V, Martín, OD, Callegari, I, Cortese, A, Delmont, E, Devaux, J, Giannotta, C, Nobie-Orazio, E, Höftberger, R, Herdewyn, S, Carvajal, A, Torné, L, Jericó-Pascual, I, Querol, L. ANTI-CASPR1 ANTIBODIES ARE ASSOCIATED WITH HLA-DRB1*03:01 ALLELES. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
CHARACTERISTICS OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY SUBTYPES: RESULTS FROM A MULTINATIONAL, REAL-WORLD SURVEY
Querol, L, Borsi, A, Gary, C, Noel, W, Karmous, W, DeCourcy, J, Wright, J, Taylor, Y, Iqbal, H, Rinaldi, S. CHARACTERISTICS OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY SUBTYPES: RESULTS FROM A MULTINATIONAL, REAL-WORLD SURVEY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
LONGITUDINAL GAIT ASSESSMENT USING A WEARABLE SYSTEM DETECTS CLINICALLY SIGNIFICANT CHANGES IN PATIENTS WITH PERIPHERAL NEUROPATHIES
Illa, CT, Pegueroles, J, Claramunt-Molet, M, Pi-Cervera, A, Heras-Delgado, A, Gascón-Fontal, J, Idelsohn-Zielonka, S, Vidal, N, Martín-Aguilar, L, Caballero-Avila, M, Lleixà, C, Llansó, L, Rojas-García, R, Querol, L, Pascual-Goñi, E. LONGITUDINAL GAIT ASSESSMENT USING A WEARABLE SYSTEM DETECTS CLINICALLY SIGNIFICANT CHANGES IN PATIENTS WITH PERIPHERAL NEUROPATHIES. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
EMPASIPRUBART (ARGX-117) IN MULTIFOCAL MOTOR NEUROPATHY: INITIAL SAFETY AND EFFICACY DATA OF THE PHASE 2 ARDA STUDY
van der Pol, WL, Peric, S, Querol, L, Hussain, Y, Cadour, S, Van de Walle, I, Persson, E, Van Hoomissen, I, Mashchenko, O, Vujcic, M, Van de Steen, O, Allen, JA. EMPASIPRUBART (ARGX-117) IN MULTIFOCAL MOTOR NEUROPATHY: INITIAL SAFETY AND EFFICACY DATA OF THE PHASE 2 ARDA STUDY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
SERUM PROTEOME IN GUILLAIN-BARRE SYNDROME USING AN APTAMER-BASED PROTEOMICS PLATFORM
Martín-Aguilar, L, Collet, R, Lleixà, C, Caballero-Avila, M, Tejada-Illa, C, Pascual-Goñi, E, Sedano-Tous, MJ, Casasnovas, C, Gutiérrez-Gutiérrez, G, Pardo-Fernández, J, Rojas, R, Turón, J, Gallardo, E, Cortés-Vicente, E, Llansó, L, García, JM, Farrés, J, Querol, L. SERUM PROTEOME IN GUILLAIN-BARRE SYNDROME USING AN APTAMER-BASED PROTEOMICS PLATFORM. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
CLINICAL AND IMMUNOLOGICAL RELAPSES ARE INFREQUENT IN PATIENTS WITH ANTI-CNTN1 AUTOIMMUNE NODOPATHY
Caballero-Avila, M, Martín-Aguilar, L, Pascual-Goñi, E, Tejada-Illa, C, Collet, R, Rojas-García, R, Gallardo, E, Martínez-Martínez, L, Doneddu, P, Nobile-Orazio, E, de Winter, J, Alonso-Jimenez, A, del Real, MA, Armangué, T, Delmont, E, Xuclà-Ferrarons, T, Roche, JC, Jauregui, A, González, A, Ortiz, N, Liong, HF, de Rivera, FJR, Sparasci, D, Ripellino, P, Pérez-Pérez, H, Guerrero-Sola, A, Vegezzi, E, Baars, A, Jacobs, B, Wieske, L, Eftimov, F, Lleixà, C, Querol, L. CLINICAL AND IMMUNOLOGICAL RELAPSES ARE INFREQUENT IN PATIENTS WITH ANTI-CNTN1 AUTOIMMUNE NODOPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
PHASE 3 TRIAL DESIGNS EVALUATING RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Lewis, RA, Allen, J, Merkies, ISJ, van Doorn, PA, Sommer, C, Wallstroem, E, Luo, XD, Alonso-Alonso, M, Atassi, N, Querol, L. PHASE 3 TRIAL DESIGNS EVALUATING RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
PHASE 2 EFFICACY AND SAFETY OF RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Querol, L, Lewis, RA, Hartung, HP, Van Doorn, PA, Wallstroem, E, Auwarter, K, Luo, XD, Alonso-Alonso, M, Atassi, N, Hughes, RAC. PHASE 2 EFFICACY AND SAFETY OF RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
PHASE 2 TRIAL OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: QUALITY-OF-LIFE AND FATIGUE
Van Doorn, PA, Querol, L, Hartung, HP, Hughes, RAC, Orsini, M, Hakimi-Hawken, N, Minor, C, Msihid, J, Alonso-Alonso, M, Atassi, N, Lewis, R. PHASE 2 TRIAL OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: QUALITY-OF-LIFE AND FATIGUE. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
PHASE 2 TRIAL OF RILIPRUBART IN CIDP: EFFECT ON COMPLEMENT BIOMARKERS AND NEUROFILAMENT LIGHT CHAIN
Querol, L, Lewis, RA, Van Doorn, PA, Hughes, RAC, Storek, M, Rajagopal, V, Chow, T, Luo, XD, Alonso-Alonso, M, Atassi, N, Hartung, HP. PHASE 2 TRIAL OF RILIPRUBART IN CIDP: EFFECT ON COMPLEMENT BIOMARKERS AND NEUROFILAMENT LIGHT CHAIN. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
CLINICAL AND GENETIC SPECTRUM OF PATIENTS WITH BAG3-RELATED NEUROMUSCULAR DISORDERS IN EUROPE
Fernandez-Eulate, G, Gitiaux, C, Thiele, S, Jungbluth, H, Audic, F, Potulska-Chromik, A, Marini-Bettolo, C, Davion, JB, de la Tassa, GM, Olivé, M, de la Hoz, CPDF, Isapof, A, Töpf, A, Walter, M, Angelini, C, Claeys, K, Kostera-Pruszczyk, A, Attarian, S, Straub, V, Domínguez-González, C, Vissing, J, Metay, C, Khraiche, D, Wahbi, K, Stojkovic, T. CLINICAL AND GENETIC SPECTRUM OF PATIENTS WITH BAG3-RELATED NEUROMUSCULAR DISORDERS IN EUROPE. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS
Allen, J, Van Doorn, PA, Basta, I, Dysgaard, T, Eggers, C, Guptill, J, Gwathmey, K, Hewamadduma, C, Hofman, E, Hussain, Y, Kuwabara, S, Le Masson, G, Leypoldt, F, Lin, J, Lipowska, M, Lowe, M, Pinter, GL, Querol, L, Simu, MA, Chang, T, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA. EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024
Assessing predictors of adequate individual buprenorphine maintenance dosage for the treatment of opioid use disorder: Listening to the patient
González-Saiz, F, Vergara-Moragues, E, Trujols, J, Alcaraz, S, de los Cobos, JP. Assessing predictors of adequate individual buprenorphine maintenance dosage for the treatment of opioid use disorder: Listening to the patient. INTERNATIONAL JOURNAL OF DRUG POLICY. 2024; 130DOI:10.1016/j.drugpo.2024.104519. PMID:39024687. IF:4.400(Q1/1D).
01/08/2024
Emotional intelligence and neurocognition profiles in first-episode psychosis: A two-year follow-up study
Clougher, D, Forte, MF, Mezquida, G, Sánchez-Torres, AM, Serra-Navarro, M, Penadés, R, Lobo, A, Pinto, AG, Panadero, R, Roldán, A, Vieta, E, de la Serna, E, Trabsa, A, Martínez-Aran, A, Torrent, C, Tortorella, A, Menculini, G, Ramos-Quiroga, JA, Cuesta, MJ, Bernardo, M, Amoretti, S. Emotional intelligence and neurocognition profiles in first-episode psychosis: A two-year follow-up study. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2024; 85DOI:10.1016/j.euroneuro.2024.05.006. PMID:39013243. IF:6.700(Q1/1D).
01/08/2024
Functioning in schizophrenia: Recommendations of an expert panel
Corripio, I, Fraguas, D, García-Portilla, MP, Olivares, JM, Sierra, P, Sánchez, P. Functioning in schizophrenia: Recommendations of an expert panel. SCHIZOPHRENIA RESEARCH. 2024; 270DOI:10.1016/j.schres.2024.06.050. PMID:38964076. IF:3.500(Q1/3D).
01/08/2024
Cortical and Subcortical Brain Alterations in Specific Phobia and Its Animal and Blood-Injection-Injury Subtypes: A Mega-Analysis From the ENIGMA Anxiety Working Group
Hilbert, K, Boeken, OJ, Langhammer, T, Groenewold, NA, Bas-Hoogendam, JM, Aghajani, M, Zugman, A, Åhs, F, Arolt, V, Beesdo-Baum, K, Björkstrand, J, Blackford, JU, Blanco-Hinojo, L, Böhnlein, J, Bülow, R, Cano, M, Cardoner, N, Caseras, X, Dannlowski, U, Domschke, K, Fehm, L, Feola, B, Fredrikson, M, Goossens, L, Grabe, HJ, Grotegerd, D, Gur, RE, Hamm, AO, Harrewijn, A, Heinig, I, Herrmann, MJ, Hofmann, D, Jackowski, AP, Jansen, A, Kaczkurkin, AN, Kindt, M, Kingsley, EN, Kircher, T, Klahn, AL, Koelkebeck, K, Krug, A, Kugel, H, Larsen, B, Leehr, EJ, Leonhardt, L, Lotze, M, Margraf, J, Michalowski, J, Muehlhan, M, Nenadic, I, Pan, PM, Pauli, P, Peñate, W, Pittig, A, Plag, J, Pujol, J, Richter, J, Rivero, FL, Salum, GA, Satterthwaite, TD, Schäfer, A, Schäfer, J, Schienle, A, Schneider, S, Schrammen, E, Schruers, K, Schulz, SM, Seidl, E, Stark, RM, Stein, F, Straube, B, Straube, T, Ströhle, A, Suchan, B, Thomopoulos, SI, Ventura-Bort, C, Visser, R, Völzke, H, Wabnegger, A, Wannemüller, A, Wendt, J, Wiemer, J, Wittchen, HU, Wittfeld, K, Wright, B, Yang, Y, Zilverstand, A, Zwanzger, P, Veltman, DJ, Winkler, AM, Pine, DS, Jahanshad, N, Thompson, PM, Stein, DJ, Van der Wee, NJ, Lueken, U. Cortical and Subcortical Brain Alterations in Specific Phobia and Its Animal and Blood-Injection-Injury Subtypes: A Mega-Analysis From the ENIGMA Anxiety Working Group. AMERICAN JOURNAL OF PSYCHIATRY. 2024; 181(8)DOI:10.1176/appi.ajp.20230032. PMID:38859702. IF:14.700(Q1/1D).
01/08/2024
The comparative safety and efficacy of anti-migraine medications and devices in migraine prophylaxis: a network meta-analysis
Nieto, RB, Láinez, MJ, Huth, M, Francis, P, Singh, S, McMaster, A, Hasham, SN, Suthar, B, Srivastava, PK. The comparative safety and efficacy of anti-migraine medications and devices in migraine prophylaxis: a network meta-analysis. JOURNAL OF HEADACHE AND PAIN. 2024; 25DOI:. PMID:. IF:7.900(Q1/1D).